Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 02, 2025 22:33 ET | Source: Fibrobiologics, Inc.

FibroBiologics gibt wissenschaftlicher Fortschritte bei der Reparatur von Hirngewebe bekannt

HOUSTON, April 03, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (im Folgenden kurz „FibroBiologics“), ein im klinischen Stadium tätiges Biotechnologieunternehmen mit über 240...
April 02, 2025 08:30 ET | Source: Fibrobiologics, Inc.

FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair

HOUSTON, April 02, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of...
March 31, 2025 16:25 ET | Source: Fibrobiologics, Inc.

FibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate Update

Proprietary master cell bank of fibroblast-based spheroids product candidate, CYWC628, completed in accordance with Good Manufacturing Practices after successfully passing all required safety testing ...
March 27, 2025 08:30 ET | Source: Fibrobiologics, Inc.

FibroBiologics Announces 2025 Annual Meeting of Stockholders

HOUSTON, March 27, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
March 21, 2025 08:30 ET | Source: Fibrobiologics, Inc.

FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting

HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
March 04, 2025 19:17 ET | Source: Fibrobiologics, Inc.

フィブロバイオロジックス (FibroBiologics)、線維芽細胞ベースの治療薬を用いたミトコンドリア活性の調節に関する新規アプローチで特許申請

この革新的な手法は、ミトコンドリアの機能異常が原因で起こる慢性疾患の新たな治療法につながる可能性が期待されている。ヒューストン発 , March 05, 2025 (GLOBE NEWSWIRE) --...
March 04, 2025 19:17 ET | Source: Fibrobiologics, Inc.

FibroBiologics meldet Patent für neuartigen Ansatz zur Modulation mitochondrialer Aktivität mithilfe von auf Fibroblasten basierten Therapeutika an

Diese innovative Methode hat das Potenzial, neue Behandlungsmöglichkeiten für chronische Erkrankungen zu erschließen, die durch mitochondriale Dysregulation verursacht werden. HOUSTON, March 05,...
March 04, 2025 19:17 ET | Source: Fibrobiologics, Inc.

FibroBiologics dépose une demande de brevet pour une nouvelle approche visant à moduler l’activité mitochondriale à l’aide de produits thérapeutiques à base de fibroblastes

Cette nouvelle méthode pourrait ouvrir la voie vers de nouvelles options thérapeutiques ciblées sur des maladies chroniques causées par un dysfonctionnement mitochondrial. HOUSTON, 05 mars 2025 ...
March 04, 2025 08:30 ET | Source: Fibrobiologics, Inc.

FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics

This innovative method has the potential to unlock new treatment options for chronic conditions driven by mitochondrial dysregulation. HOUSTON, March 04, 2025 (GLOBE NEWSWIRE) -- FibroBiologics,...
February 27, 2025 08:30 ET | Source: Fibrobiologics, Inc.

FibroBiologics and Charles River Announce Completion and Release of CYWC628 Master Cell Bank for the Manufacturing of Fibroblast Cell-based Wound Healing Therapeutic

HOUSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics") and Charles River Laboratories (“Charles River”), a leading, global provider of drug discovery,...